Biotechnology · Boston, Massachusetts, United States
$30.44
-0.70% (-$0.21)2026-07-09
Smart-Money SignalNeutral · 52/100— Insiders are net sellers over 90 days (-$2.3M, 11 sales vs 14 buys)
Revenue$0
Net Income-$45.5M
EPS$-0.32
Market Cap$4.4B
Price Performance
Historical data including institutional events
Company Profile
M
Malte Peters
CEO & Executive Director
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer.
The company was founded in 2017 and is headquartered in Boston, Massachusetts.
